Header cover image

Danish (OMX) Pharma Industry Analysis

UpdatedJun 07, 2024
DataAggregated Company Financials
Companies4
  • 7D6.0%
  • 3M7.6%
  • 1Y76.0%
  • YTD39.3%

In the last week, the Pharma industry is up 2.6%, with Novo Nordisk up 6.2%. During this same period, the ALK-Abelló underperformed, falling 5.8%. This takes the industry's 12 month performance to a gain of 70%. As for the next few years, earnings are expected to grow by 13% per annum.

Industry Valuation and Performance

Has the Danish Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 07 Jun 2024kr.4.4tkr.269.3bkr.92.2b48.4x47.5x16.3x
Sun, 05 May 2024kr.3.8tkr.269.1bkr.92.1b42.3x41.7x14.3x
Tue, 02 Apr 2024kr.4.0tkr.257.0bkr.86.4b47x46.2x15.5x
Thu, 29 Feb 2024kr.3.8tkr.257.0bkr.86.4b44.5x43.8x14.7x
Sat, 27 Jan 2024kr.3.3tkr.238.8bkr.78.2b43.3x42.5x13.9x
Mon, 25 Dec 2023kr.3.2tkr.238.8bkr.78.2b41.1x40.3x13.2x
Wed, 22 Nov 2023kr.3.2tkr.238.8bkr.78.2b41.5x40.7x13.3x
Fri, 20 Oct 2023kr.3.1tkr.225.4bkr.70.1b45.5x44.4x13.8x
Sun, 17 Sep 2023kr.3.0tkr.225.4bkr.70.1b44.3x43.3x13.5x
Tue, 15 Aug 2023kr.2.8tkr.224.8bkr.69.9b41.2x40.4x12.6x
Thu, 13 Jul 2023kr.2.4tkr.211.8bkr.63.8b37.9x37x11.2x
Sat, 10 Jun 2023kr.2.5tkr.211.8bkr.63.8b40x39.2x11.8x
Mon, 08 May 2023kr.2.5tkr.211.1bkr.63.4b40.2x39.6x11.9x
Wed, 05 Apr 2023kr.2.5tkr.199.7bkr.57.8b43.9x43.2x12.5x
Fri, 03 Mar 2023kr.2.3tkr.199.7bkr.57.8b40.8x40.1x11.6x
Sun, 29 Jan 2023kr.2.2tkr.189.2bkr.54.7b40.5x40x11.6x
Tue, 27 Dec 2022kr.2.2tkr.189.2bkr.54.7b40x39.4x11.4x
Thu, 24 Nov 2022kr.2.0tkr.189.2bkr.54.7b36.1x35.7x10.3x
Sat, 22 Oct 2022kr.1.8tkr.178.4bkr.52.1b34.9x34.9x10.2x
Mon, 19 Sep 2022kr.1.8tkr.178.4bkr.52.1b33.6x33.6x9.8x
Wed, 17 Aug 2022kr.1.8tkr.177.9bkr.52.0b34.5x34.8x10.2x
Fri, 15 Jul 2022kr.1.9tkr.169.5bkr.50.7b37.2x37.5x11.2x
Sun, 12 Jun 2022kr.1.8tkr.169.5bkr.50.7b36.1x36.4x10.9x
Tue, 10 May 2022kr.1.8tkr.169.2bkr.50.9b34.3x34.5x10.4x
Thu, 07 Apr 2022kr.1.9tkr.161.0bkr.49.3b37.5x37.7x11.5x
Sat, 05 Mar 2022kr.1.7tkr.161.0bkr.49.3b33.4x33.6x10.3x
Mon, 31 Jan 2022kr.1.5tkr.154.9bkr.48.2b31.5x31.5x9.8x
Wed, 29 Dec 2021kr.1.7tkr.154.9bkr.48.2b36.1x36.1x11.2x
Fri, 26 Nov 2021kr.1.7tkr.154.9bkr.48.2b35.6x35.5x11x
Sun, 24 Oct 2021kr.1.6tkr.150.5bkr.46.4b34.9x34.9x10.7x
Tue, 21 Sep 2021kr.1.5tkr.150.5bkr.46.4b32.8x32.7x10.1x
Thu, 19 Aug 2021kr.1.6tkr.150.5bkr.46.4b34.6x34.6x10.7x
Price to Earnings Ratio

27.6x


Total Market Cap: kr.1.3tTotal Earnings: kr.46.4bTotal Revenue: kr.150.5bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Pharma Industry Price to Earnings3Y Average 38.3x202220232024
Current Industry PE
  • Investors are optimistic on the Danish Pharmaceuticals industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 45.8x which is higher than its 3-year average PE of 38.3x.
  • The 3-year average PS ratio of 11.8x is lower than the industry's current PS ratio of 15.7x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 26% per year over the last three years.
  • Revenues for these companies have grown 21% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare industry?

DK Market4.01%
Healthcare5.53%
Pharma6.01%
Pharma6.01%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NOVO B Novo Nordiskkr.984.006.1%
+kr.251.3b		80.3%PE48.9x
Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy Policy
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

ALK B

kr.143.70

ALK-Abelló

7D

-5.8%

1Y

66.6%

A Look At The Intrinsic Value Of ALK-Abelló A/S (CPH:ALK B)

Jun 07
A Look At The Intrinsic Value Of ALK-Abelló A/S (CPH:ALK B)

HLUN B

kr.36.92

H. Lundbeck

7D

-2.2%

1Y

1.3%

STENO

kr.4.26

Stenocare

7D

-4.1%

1Y

-38.1%

NOVO B

kr.984.00

Novo Nordisk

7D

6.1%

1Y

80.3%

Novo Nordisk's (CPH:NOVO B) Promising Earnings May Rest On Soft Foundations

May 09
Novo Nordisk's (CPH:NOVO B) Promising Earnings May Rest On Soft Foundations